Gilead Sciences (GILD) 107.51 $GILD
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:40PM CDT
RedHill Biopharma Ltd. (RDHL) recently provided an update on the ongoing phase III study ERADICATE Hp, on pipeline candidate RHB-105 for Helicobacter pylori infection (H. pylori).
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:20PM CDT
Amgen Inc. (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine.
Most active Nasdaq-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:50PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) has resolved the issues mentioned in the FDA's warnings letter on the marketing and sales of Juxtapid in the U.S.
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:00PM CDT
MediciNova's (MNOV) shares have gained 7.7% ever since the company announced that it will be starting a clinical study on MN-166.
Allergan Seeks Court Order to Stop Valeant, Affiliates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Allergan (AGN) is being relentlessly pursued by Valeant Pharmaceuticals International (VRX) since Apr 2014.
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:30PM CDT
Repros Therapeutics Inc. (RPRX) announced positive top-line data on its secondary hypogonadism candidate, Androxal, from a pivotal phase III study.
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the RadioShack Corp. (NYSE:RSH-Free Report), Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report), Shire (Nasdaq:SHPG-Free Report) and Gilead Sciences Inc. (Nasdaq:GILD-Free Report).
Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 28, 8:01AM CDT
It isn't surprising to see that the European Commission has given Bristol-Myers Squibb the go-ahead for daclatasvir, Bristol's promising new hepatitis C treatment. Europe had already shown its willingness to support the use of daclatasvir, which...
Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - Thu Aug 28, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global
Q2 Earnings Season in Rearview Mirror - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Thu Aug 28, 3:39AM CDT
Q2 Earnings Season in Rearview Mirror - Earnings Outlook
Q2 Earnings Season in Rearview Mirror - Earnings Trends
Sheraz Mian - Zacks Investment Research - Thu Aug 28, 3:39AM CDT
Q2 Earnings Season in Rearview Mirror - Earnings Trends
After Yesterday's Rally of 1.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.07% Rise
Comtex SmarTrend(R) - Wed Aug 27, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences (GILD) Approaches New Upside Target of $110.54
Comtex SmarTrend(R) - Wed Aug 27, 11:42AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next upside pivot targets of $110.54 and $114.49.
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:40PM CDT
RedHill Biopharma Ltd. (RDHL) recently provided an update on the ongoing phase III study ERADICATE Hp, on pipeline candidate RHB-105 for Helicobacter pylori infection (H. pylori).
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:20PM CDT
Amgen Inc. (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine.
Most active Nasdaq-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:50PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) has resolved the issues mentioned in the FDA's warnings letter on the marketing and sales of Juxtapid in the U.S.
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:00PM CDT
MediciNova's (MNOV) shares have gained 7.7% ever since the company announced that it will be starting a clinical study on MN-166.
Allergan Seeks Court Order to Stop Valeant, Affiliates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Allergan (AGN) is being relentlessly pursued by Valeant Pharmaceuticals International (VRX) since Apr 2014.
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:30PM CDT
Repros Therapeutics Inc. (RPRX) announced positive top-line data on its secondary hypogonadism candidate, Androxal, from a pivotal phase III study.
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the RadioShack Corp. (NYSE:RSH-Free Report), Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report), Shire (Nasdaq:SHPG-Free Report) and Gilead Sciences Inc. (Nasdaq:GILD-Free Report).
Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 28, 8:01AM CDT
It isn't surprising to see that the European Commission has given Bristol-Myers Squibb the go-ahead for daclatasvir, Bristol's promising new hepatitis C treatment. Europe had already shown its willingness to support the use of daclatasvir, which...
Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - Thu Aug 28, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global
Q2 Earnings Season in Rearview Mirror - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Thu Aug 28, 3:39AM CDT
Q2 Earnings Season in Rearview Mirror - Earnings Outlook
Q2 Earnings Season in Rearview Mirror - Earnings Trends
Sheraz Mian - Zacks Investment Research - Thu Aug 28, 3:39AM CDT
Q2 Earnings Season in Rearview Mirror - Earnings Trends
After Yesterday's Rally of 1.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.07% Rise
Comtex SmarTrend(R) - Wed Aug 27, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences (GILD) Approaches New Upside Target of $110.54
Comtex SmarTrend(R) - Wed Aug 27, 11:42AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next upside pivot targets of $110.54 and $114.49.
